Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 1,204 INR
Change Today -6.45 / -0.53%
Volume 142.6K
TRP On Other Exchanges
Symbol
Exchange
OTC US
As of 6:28 AM 06/3/15 All times are local (Market data is delayed by at least 15 minutes).

torrent pharmaceuticals ltd (TRP) Snapshot

Open
1,219
Previous Close
1,210
Day High
1,231
Day Low
1,189
52 Week High
04/15/15 - 1,335
52 Week Low
06/5/14 - 607.10
Market Cap
203.7B
Average Volume 10 Days
101.9K
EPS TTM
44.38
Shares Outstanding
169.2M
EX-Date
06/15/15
P/E TM
27.1x
Dividend
11.25
Dividend Yield
0.83%
Current Stock Chart for TORRENT PHARMACEUTICALS LTD (TRP)

Related News

No related news articles were found.

torrent pharmaceuticals ltd (TRP) Related Businessweek News

No Related Businessweek News Found

torrent pharmaceuticals ltd (TRP) Details

Torrent Pharmaceuticals Limited, together with its subsidiaries, manufactures and sells branded and unbranded generic pharmaceutical products in India and internationally. The company offers its products in therapeutic areas of cardiovascular, central nervous system, gastrointestinal, anti-infective, diabetology, and pain management areas. It offers products in the form of tablets, capsules, and parenterals. The company’s active pharmaceutical ingredients comprise nicorandil, risperidone, venlafaxine hydrochloride, ropinarole hydrochloride, duloxetine hydrochloride, ormeloxifen hydrochloride, nebivolol hydrochloride, lamotrigine, sertraline hydrochloride, and clopidogrel bisulphate, as well as atomoxatine hydrochloride, rivastigmine hydrogen tartrate, and esomeprazole sodium. It also provides contract manufacturing services primarily for human insulin. The company was formerly known as Trinity Laboratories and changed its name to Torrent Pharmaceuticals Limited in 1971. Torrent Pharmaceuticals Limited was founded in 1959 and is based in Ahmedabad, India. Torrent Pharmaceuticals Limited is a subsidiary of Torrent Private Limited.

Founded in 1959

torrent pharmaceuticals ltd (TRP) Top Compensated Officers

Executive Vice Chairman, Managing Director, M...
Total Annual Compensation: 313.0K
Director of Research & Development, Whole-Tim...
Total Annual Compensation: 27.4M
Compensation as of Fiscal Year 2014.

torrent pharmaceuticals ltd (TRP) Key Developments

Torrent Pharmaceuticals Ltd. Announces Resignation of Bhavna Doshi, Independent Directors

Torrent Pharmaceuticals Ltd. announced that Bhavna Doshi, Independent Directors, has resigned from the Board of Directors of the company with effect from the conclusion of the Board meeting held on May 15, 2015. The Board has accepted her resignation at the Board Meeting held on May 15, 2015.

Torrent Pharmaceuticals Ltd. Recommends Final Dividend, Payable on or Around July 31, 2015

Torrent Pharmaceuticals Ltd. announced that the Board of Directors of the company at its meeting held on May 15, 2015, has recommended a final dividend of INR 6.25 per equity share of INR 5.00 each fully paid up further to the interim dividend of INR 5.00 per equity share paid during the last quarter. These final dividend amounts, if declared by the Shareholders are proposed to be paid /dispatched on or around July 31, 2015.

Torrent Pharmaceuticals Ltd. Reports Audited Standalone and Consolidated Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2015

Torrent Pharmaceuticals Ltd. reported audited standalone and consolidated earnings results for the fourth quarter and full year ended March 31, 2015. For the quarter, on standalone basis, reported net income from operations of INR 8,970 million compared to INR 9,540 million a year ago. Profit from operations before other income and finance costs was INR 910 million compared to INR 3,180 million a year ago. Profit from ordinary activates before tax was INR 1,450 million compared to INR 3,080 million a year ago. Net profit was INR 1,030 million or INR 6.12 per basic and diluted share before and after extraordinary items compared to INR 2,520 million or INR 14.89 per basic and diluted share before and after extraordinary items a year ago. For the year, on standalone basis, reported net income from operations of INR 34,760 million compared to INR 33,650 million a year ago. Profit from operations before other income and finance costs was INR 6,640 million compared to INR 9,800 million a year ago. Profit from ordinary activates before tax was INR 7,960 million compared to INR 9,580 million a year ago. Net profit was INR 6,230 million or INR 36.83 per basic and diluted share before and after extraordinary items compared to INR 7,620 million or INR 45.05 per basic and diluted share before and after extraordinary items a year ago. For the quarter, on consolidated basis, reported net income from operations of INR 11,540 million compared to INR 12,250 million a year ago. Profit from operations before other income and finance costs was INR 1,020 million compared to INR 3,270 million a year ago. Profit from ordinary activates before tax was INR 1,550 million compared to INR 3,170 million a year ago. Net profit was INR 1,300 million or INR 7.70 per basic and diluted share before and after extraordinary items compared to INR 2,440 million or INR 14.44 per basic and diluted share before and after extraordinary items a year ago. EBITDA was INR 2,590 million compared to INR 3,500 million a year ago. For the year, on consolidated basis, reported net income from operations of INR 46,530 million compared to INR 41,840 million a year ago. Profit from operations before other income and finance costs was INR 8,290 million compared to INR 8,650 million a year ago. Profit from ordinary activates before tax was INR 9,400 million compared to INR 8,440 million a year ago. Net profit was INR 7,510 million or INR 44.38 per basic and diluted share before and after extraordinary items compared to INR 6,640 million or INR 39.23 per basic and diluted share before and after extraordinary items a year ago. EBITDA was INR 12,800 million compared to INR 9,420 million a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TRP:IN 1,203.60 INR -6.45

TRP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Divi's Laboratories Ltd 1,771 INR -42.15
Ipca Laboratories Ltd 632.40 INR -19.80
Jubilant Life Sciences Ltd 165.05 INR -5.70
Piramal Enterprises Ltd 962.25 INR +8.85
Wockhardt Ltd 1,350 INR -52.00
View Industry Companies
 

Industry Analysis

TRP

Industry Average

Valuation TRP Industry Range
Price/Earnings 26.7x
Price/Sales 4.3x
Price/Book 8.0x
Price/Cash Flow 21.3x
TEV/Sales 3.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TORRENT PHARMACEUTICALS LTD, please visit www.torrentpharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.